(Q33966254)

30 July 2017

1 reference

title

Novel compounds in preclinical/early clinical development for the treatment of HIV infections (English)

1 reference

30 July 2017

De Clercq E

1

1 reference

30 July 2017

publication date

1 July 2000

1 reference

Reviews in Medical Virology

30 July 2017

published in

1 reference

30 July 2017

volume

10

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

255-277

1 reference

Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Management of CMV retinitis in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Sulfated polysaccharides extracted from sea algae as potential antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

A general model for the surface glycoproteins of HIV and other retroviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Mechanism of anti-HIV activity of succinylated human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Characterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Chemokines--chemotactic cytokines that mediate inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

HIV-1 entry inhibitors in the side pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

FR901724, a novel anti-human immunodeficiency virus (HIV) peptide produced by Streptomyces, shows synergistic antiviral activities with HIV protease inhibitor and 2',3'-dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

ADA, a potential anti-HIV drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

(-)-6-Chloro-2-[(1-furo[2, 3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Synthesis and anti-human immunodeficiency virus type 1 integrase activity of hydroxybenzoic and hydroxycinnamic acid flavon-3-yl esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Inhibition of human immunodeficiency virus type-1 integrase by curcumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

The molecular basis of HIV capsid assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Azodicarbonamide inhibits T-cell responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

Recent developments in HIV protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

A Convergent, Scalable Synthesis of HIV Protease Inhibitor PNU-140690

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1654%28200007%2F08%2910%3A4%3C255%3A%3AAID-RMV282%3E3.0.CO%3B2-6

10.1002/1099-1654(200007/08)10:4<255::AID-RMV282>3.0.CO;2-6

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference